Later, novel families of NMT inhibitors were identified by high throughput screening (HTS) efforts.7,18–20 A selection of different chemotypes are under active development against NMT for numerous indications (Fig. S1‡), and an NMT inhibitor has recently entered the Medicines for Malaria Venture (MMV) development pipeline for the treatment of the lethal form of malaria caused by Plasmodium falciparum. Here, NMT1 is linked to malaria.